Donanemab

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Future direction for anti-amyloid immunotherapies

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Is amyloid lowering still a valid approach in Alzheimer’s disease?

Important developments in dementia: biomarkers & clinical trials

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Aducanumab: what’s the latest?

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab